One in 8 women is Diagnosed with breast cancer.
The PI3Kinase pathway plays a significant role in treatment resistant breast cancer.
Triple-negative breast cancer (TNBC) accounts for about 10-15% of all breast cancers. Triple-negative breast cancer cells do not express estrogen or progesterone receptors and also don’t make a protein called HER2.
Unique Treatment Challenges of TNBC
Resistance to
Hormone therapies and HER2 biologics
Chemotherapies or Radiation
Immunotherapy
1
Suppression of
immune molecules &
lysosome biogenesis
2
Overly active cell growth pathways including PI3K
3
2024
Entering final preclinical studies in Glioblastoma with Medical College Of Wisonsin
2024
Begin new study with Brown University on inhibiting Diffuse intrinsic pontine gliomas (DIPGS) brain tumors in children
2024
Targeting for Phase 1
Clinical Trial in Glioblastoma
2025
Targeting for Phase 2 Clinical Trial in Glioblastoma mid-
2025
Targeting for Triple Negative Breast Cancer Phase 1 Clinical Trial with University of Colorado mid-year.
2024
Begin investigative
studies on the
inhibition of psoriasis.
Global Cancer Technology is offering accredited investors pre-IPO shares. Please contact us for additional investment information.